- Home
- LSH vs NRSN Comparison
LSH vs NRSN Comparison
Compare LSH & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSH
- NRSN
- Stock Information
- Founded
- LSH 2018
- NRSN 2017
- Country
- LSH United States
- NRSN Israel
- Employees
- LSH N/A
- NRSN N/A
- Industry
- LSH
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- LSH
- NRSN Health Care
- Exchange
- LSH NYSE
- NRSN Nasdaq
- Market Cap
- LSH 18.0M
- NRSN 17.8M
- IPO Year
- LSH 2024
- NRSN 2021
- Fundamental
- Price
- LSH $2.46
- NRSN $1.28
- Analyst Decision
- LSH
- NRSN Hold
- Analyst Count
- LSH 0
- NRSN 1
- Target Price
- LSH N/A
- NRSN N/A
- AVG Volume (30 Days)
- LSH 43.2K
- NRSN 519.7K
- Earning Date
- LSH 02-01-2025
- NRSN 12-31-2024
- Dividend Yield
- LSH N/A
- NRSN N/A
- EPS Growth
- LSH N/A
- NRSN N/A
- EPS
- LSH N/A
- NRSN N/A
- Revenue
- LSH $18,248,233.00
- NRSN N/A
- Revenue This Year
- LSH N/A
- NRSN N/A
- Revenue Next Year
- LSH N/A
- NRSN N/A
- P/E Ratio
- LSH N/A
- NRSN N/A
- Revenue Growth
- LSH 28.38
- NRSN N/A
- 52 Week Low
- LSH $2.10
- NRSN $0.51
- 52 Week High
- LSH $5.37
- NRSN $2.33
- Technical
- Relative Strength Index (RSI)
- LSH N/A
- NRSN 60.53
- Support Level
- LSH N/A
- NRSN $0.96
- Resistance Level
- LSH N/A
- NRSN $1.42
- Average True Range (ATR)
- LSH 0.00
- NRSN 0.15
- MACD
- LSH 0.00
- NRSN 0.04
- Stochastic Oscillator
- LSH 0.00
- NRSN 77.05
About LSH LAKESIDE HOLDING LTD
Lakeside Holding Ltd i an integrated cross-border supply chain solution provider with a strategic focus on the Asian market including China and South Korea. It provides customized cross-border ocean freight solutions and airfreight solutions in the U.S, including cross-border freight consolidation and forwarding services; customs clearance services; warehousing and distribution services and U.S. domestic ground transportation services.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.